Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.53 |
| ▸ | PDE4A | P27815 | 4/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 4/20 | 0.50 |
| ▸ | BRD2 | P25440 | 2/20 | 0.50 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.50 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7461429 | 0.86 | MAPK1 (0.60) | MAPK1CYP3A4PMP22SMN1; SMN2KDM4E | |
| SCHEMBL7454403 | 0.85 | PDE4A (0.61) | MAPK1KDM4ELMNAPOLBADORA2A | |
| SCHEMBL17609493 | 0.84 | SMN1; SMN2 (0.55) | MAPK1CYP3A4PMP22SMN1; SMN2KDM4E | |
| SCHEMBL381684 | 0.84 | PDE4A (0.71) | MAPK1CYP3A4PMP22SMN1; SMN2KDM4E | |
| SCHEMBL1495090 | 0.82 | PDE4A (0.76) | MAPK1CYP3A4PMP22SMN1; SMN2KDM4E | |
| SCHEMBL4566277 | 0.80 | MEN1 (0.77) | MAPK1CYP3A4PMP22SMN1; SMN2KDM4E | |
| SCHEMBL6661580 | 0.80 | BRD4 (0.51) | MAPK1CYP3A4KDM4ELMNAPOLB | |
| SCHEMBL16675435 | 0.80 | MAPK1 (0.64) | MAPK1CYP3A4PMP22SMN1; SMN2KDM4E | |
| SCHEMBL10955005 | 0.80 | MAPK1 (0.64) | MAPK1CYP3A4PMP22SMN1; SMN2KDM4E | |
| SCHEMBL16675439 | 0.79 | ALDH1A1 (0.53) | MAPK1CYP3A4PMP22SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240694-A1 | CATALYSTS AND METHODS FOR RING OPENING METATHESIS POLYMERIZATION | UNITED STATES DEPARTMENT OF ENERGY | 2017-08-24 | — | — | US | disclosed |
| US-20070105878-A1 | Purine formulations and methods for managing disorders | REAUME ANDREW | 2007-05-10 | — | — | US | disclosed |
| US-20070105878-A1 | Purine formulations and methods for managing disorders | REAUME ANDREW | 2007-05-10 | — | — | US | disclosed |
| WO-2007041506-A1 | PURINE FORMULATIONS AND METHODS FOR MANAGING DISORDERS | MELIOR DISCOVERY, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| CN-1098686-C | Use of xanthine derivatives for reducing the pathological hyper-reactivity of eosinophilic granulocytes, novel xanthine compounds and process for producing them | AVENTIS HARMACEUTICAL DEUTSCHE (DE) | 2003-01-15 | — | — | CN | disclosed |
| US-20020010333-A1 | Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation | HOECHST AKTIENGESELLSCHAFT | 2002-01-24 | — | — | US | disclosed |
| EP-0771813-B1 | Alkylxanthine phosphonates and alkylxanthine phosphine oxydes and their use as medicines | HOECHST AG (DE) | 2002-01-16 | — | — | EP | disclosed |
| CN-1064361-C | Xanthine compounds having terminally aminated alkynol side chains | HOECHST AG (DE) | 2001-04-11 | — | — | CN | disclosed |
| EP-0811623-B1 | Xanthine derivatives with end-aminated alkynol side chains | HOECHST AG (DE) | 2001-04-04 | — | — | EP | disclosed |
| US-5965555-A | TREATMENT AND/OR PROPHYLAXIS OF CEREBROVASCULAR DISORDERS CHARACTERIZED BY DAMAGE CAUSED BY ISCHEMIA AND SUBSEQUENT NECROTIC DESTRUCTION OF NERVE CELLS(NEURONS) | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-10-12 | — | — | US | disclosed |
| CN-1145029-A | Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophils, xanthine compounds and process for their preparation | HOECHST AG (DE) | 1997-03-12 | — | — | CN | disclosed |
| EP-0758239-A1 | USE OF XANTHINE DERIVATIVES FOR REDUCING THE PATHOLOGICAL HYPER-REACTIVITY OF EOSINOPHILIC GRANULOCYTES, NOVEL XANTHINE COMPOUNDS AND PROCESS FOR PRODUCING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-02-19 | — | — | EP | disclosed |
| EP-0557876-B1 | Use of xanthine derivatives for the treatment of muscle damage subsequent to complete interruption of blood circulation | HOECHST AG (DE) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995026727-A1 | USE OF XANTHINE DERIVATIVES FOR REDUCING THE PATHOLOGICAL HYPER-REACTIVITY OF EOSINOPHILIC GRANULOCYTES, NOVEL XANTHINE COMPOUNDS AND PROCESS FOR PRODUCING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-10-12 | — | — | WO | disclosed |
| CN-1026112-C | Process of preparing hydroxyalkylxanthines and medicines containing them and uses thereof | HOECHST AG (DE) | 1994-10-05 | — | — | CN | disclosed |
| EP-0557876-A1 | Use of xanthine derivatives for the treatment of muscle damage subsequent to complete interruption of blood circulation | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-09-01 | — | — | EP | disclosed |
| EP-0268585-B1 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | disclosed |
| US-4833146-A | BRAINS, BLOOD DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-05-23 | — | — | US | disclosed |
| EP-0268585-A1 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF. | HOECHST AG (DE) | 1988-06-01 | — | — | EP | disclosed |
| WO-1987000523-A2 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105878-A1 | Purine formulations and methods for managing disorders | TPMT, UMPS, SLC10A2 | MAPK1 2268/4885CYP3A4 2871/4885PMP22 588/4885 |
| US-20020010333-A1 | Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation | EPX, XDH, MPO | MAPK1 1635/4885CYP3A4 538/4885PMP22 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.